ONCOLOGY BILLING SERVICES
Every Treatment Has a Clinical Plan. Its Revenue Needs One, Too.
Oncology reimbursement depends on more than submitting a clean claim. The authorized regimen, administered dose, infusion record, drug source, and payer payment all need to tell the same story.
Billing Horizon brings billing, coding review, denial follow-up, and revenue reconciliation into an oncology workflow built around those handoffs.
Medical & hematologic oncology
Radiation oncology
Infusion services
One visit. Multiple reimbursement dependencies.
Drug line ≠ administration line
Track both to resolution →
Illustrative workflow, not patient data or a performance report.
WHERE ONCOLOGY REVENUE GETS STUCK
A Claim Can Be Accepted. And Still Leave Treatment Unpaid.
Clearinghouse acceptance confirms receipt, not coverage or correct reimbursement. Oncology follow-up has to locate the failure at the treatment, claim line, and payment level.
01 / BEFORE TREATMENT
The regimen changed. The approval did not.
A substituted drug, revised course, or different treatment location can change the authorization requirements. Review the approved drug and services against the current order, dates, units, and site before the next claim moves forward.
02 / AT CHARGE CAPTURE
The dose is correct. The claim units are not.
Clinical milligrams, HCPCS billing units, and payer-required NDC quantities are different measures. A conversion error can affect drug reimbursement even when the administration service pays.
03 / AFTER PAYMENT
The account has a payment. The drug line has a variance.
Account-level totals can conceal denied drug lines, missing administration charges, or a contracted allowance discrepancy. Reconcile the remit by service line before treating the episode as complete.
AUTHORIZATION & PAYER RULES
Approval Needs to Follow the Actual Treatment.
Build an authorization record that can be compared with the treatment order and claim. Eligibility, benefit coverage, referral requirements, and authorization are separate checks; one does not replace the others.
Medicare: Check the applicable coverage policy, medically accepted indication requirements, and local contractor guidance for the drug and service.
Commercial plans: Confirm regimen, specialty pharmacy or buy-and-bill requirements, approved location, and whether a treatment change needs a new request.
Medicaid: Review the state and managed care plan’s drug, NDC reporting, provider enrollment, and authorization rules separately.
2026 PAYER WATCH / SCOPED UPDATE
Maintenance therapy can trigger a site-of-care review.
Beginning August 1, 2026, UnitedHealthcare extended site-of-care review to certain maintenance or monotherapy oncology drugs for its commercial fully insured, level funded, and ASO plans.
That means a shift from combination treatment to monotherapy may create a new billing dependency: whether the outpatient hospital setting is medically necessary under that policy.
Operational checkpoint
Recheck the drug, plan, and location when the regimen changes. Do not apply this policy to every payer or every oncology medication.
DRUG REVENUE INTEGRITY
The Financial Risk Is Often Inside the Drug Line.
For buy-and-bill services, drug acquisition and payer reimbursement are separate transactions. The billing review needs to connect product, dose, source, coding, and payment without assuming that an administration payment closes the drug balance.
UNIT CONVERSION / HYPOTHETICAL EXAMPLE
J9271 · pembrolizumab
200
mg administered
÷
1
mg per HCPCS unit
=
200
HCPCS units
A documented dose must be converted using the code’s billing descriptor. This example illustrates billing arithmetic, not a recommended dose. NDC quantity reporting is a separate payer requirement.
Product and source
Match the actual drug or biosimilar to the date-specific HCPCS code. Identify practice-purchased, specialty pharmacy supplied, and replacement products before charging.
Administered and discarded amounts
For applicable separately payable Medicare Part B drugs from single-dose containers, JW identifies discarded amounts; JZ identifies no discarded amount. Vial documentation and billing-unit rounding need review.
Expected versus received payment
Use the applicable contract or payment methodology and date of service. Medicare drug payment files change quarterly; hospital outpatient status and packaging require a separate setting-specific review.
ONCOLOGY CODING & CHARGE REVIEW
Code the Documented Service. Then Test the Claim Logic.
A diagnosis and a drug code are only part of the record. Administration sequencing, time, route, separate evaluation work, and current edits determine whether the complete claim represents the encounter.
96360–96379 / 96401–96549
Start with the administration record.
Capture route, access site, start and stop times, sequence, and the administered agent. An initial service is not simply the first item on a charge sheet. Medicare NCCI generally allows one initial administration service per encounter, with limited exceptions such as medically necessary separate IV access sites.
Review hydration and supportive medication charges for distinct documented services. A same-day office E/M service needs separately identifiable work; modifier 25 is not an automatic companion to an infusion.
REVIEW INPUTS
Signed order + treatment record
Timing + route + access
Separate E/M documentation
CPT guidance + applicable NCCI edits
Documentation drives review. A modifier does not create a separate service.
HCPCS / ICD-10-CM / PRODUCT CROSSWALK
Keep the drug, diagnosis, and encounter purpose aligned.
Review the administered product, code effective date, HCPCS unit descriptor, and payer-required NDC data. Biosimilar substitution needs a product-specific code check, not a copied charge from the prior cycle.
ICD-10-CM review distinguishes active malignancy, personal history, treatment-related conditions, and the documented reason for the encounter. Z51.11 and Z51.12 identify encounters for antineoplastic chemotherapy and immunotherapy respectively when supported and applicable; they do not replace the underlying malignancy detail. For encounters chiefly for antineoplastic treatment, sequencing must follow the applicable ICD-10-CM guidelines, including the FY 2027 version effective October 1, 2026.
REVIEW INPUTS
Drug name + strength + source
Actual dose + applicable waste
Code / product effective date
Documented indication + diagnosis
Code examples are review points, not universal claim instructions.
2026 RADIATION DELIVERY CHANGES
An old charge map can become a current-year denial.
For 2026, external beam treatment delivery is consolidated into revised codes 77402, 77407, and 77412. Former IMRT delivery codes 77385 and 77386 and the delivery G-code structure were removed.
Image guidance is another checkpoint: its technical component is included in the revised delivery services, while 77387 addresses the professional component when applicable. Review the treatment-delivery mapping, component billing, and payer implementation instead of carrying forward the prior year’s charge configuration.
2026 CONFIGURATION REVIEW
Treatment delivery complexity
Professional / technical components
Deleted code replacement mapping
Plan-specific processing readiness
PROVIDER TYPES & CARE MODELS
Oncology Is a Specialty. It Is Not a Single Billing Model.
We structure the billing discussion around the clinicians, treatment setting, and revenue responsibilities in your organization. Professional claims and facility billing requirements need their own scope and ownership.
Medical Oncology & Hematology
Medical oncologists, hematologist-oncologists, and hematology practices: antineoplastic treatment, supportive therapies, drug claims, evaluations, and ongoing treatment follow-up.
Radiation Oncology
Radiation oncologists and treatment programs: planning and delivery charge reconciliation, professional and technical components, current code mappings, and authorization alignment.
Surgical & Gynecologic Oncology
Surgical and gynecologic oncologists: operative documentation, procedure-specific coding, global period review, separate E/M work, and coordination with systemic treatment billing.
Pediatric Oncology
Pediatric oncologists and hematology programs: regimen-specific approvals, state Medicaid or commercial requirements, rendering-provider setup, and care delivered across settings.
Infusion Centers & Advanced Practice Clinicians
Office infusion operations, oncology nurse practitioners, and physician assistants: administration records, supervision and payer billing requirements, and the rendering clinician on each claim.
Multidisciplinary & Hospital Programs
Integrated cancer centers and hospital-associated teams: defined handoffs between professional services, facility charges, pharmacy records, and radiation or infusion departments.
Tell Us About Your Oncology Practice
No obligation. No pressure. Just a practical conversation about your revenue cycle.
AI-ASSISTED ONCOLOGY WORKFLOWS
Find the Mismatch Earlier. Keep the Decision Accountable.
AI-assisted review can surface an unusual unit pattern, a recurring payer denial, or a missing relationship between authorization and claim data. It supports the work queue; it does not decide medical necessity or invent missing clinical evidence.
Signal → evidence → human resolution
Patient data access, permitted tool use, and audit trails belong in the operating design. AI output must be checked against the source record and applicable rules before a claim is changed.
ONCOLOGY REVENUE CYCLE MANAGEMENT
Make Every Unpaid Line Explainable.
An aging report tells you how long a balance has remained. It does not tell you whether the next step is an authorization correction, coding review, appeal, or contract inquiry.
Our review approach separates rejections, adjudicated denials, underpayments, and unresolved status. Work is assigned with a cause, supporting evidence, deadline, and next action. Appeal and timely filing windows are checked against the actual plan.
Drug reimbursement
Payment below expected allowance
Next: validate contract and remit
Administration service
Bundling or sequencing edit
Next: review record and edit pair
Treatment authorization
Claim outside approved scope
Next: compare approval and regimen
Unresolved payer status
No adjudication confirmed
Next: establish receipt and follow-up date
ONCOLOGY EMR / EHR WORKFLOWS
Keep the Clinical Context Connected to the Charge.
Oncology systems hold treatment plans, medication orders, administration details, and charge information in different places. We assess how your configuration moves those records into billing and where reconciliation is required.
Clinical source
Regimen · medication · delivery record
→
Charge reconciliation
Product · units · services · components
→
Claim & payment
Submission · remit · exception ownership
OncoEMR
Epic / Beacon
ARIA
MOSAIQ
eClinicalWorks
athenahealth
NextGen Healthcare
Supports 50+ Additional EMR / EHR Platforms
Platform examples describe environments to review, not vendor partnerships or a promise of a prebuilt interface. Access, exports, available integrations, and charge workflows are confirmed during assessment.
TRANSITION & CONTINUOUS REVIEW
Move the Billing Responsibility. Keep the Treatment Work Visible.
Before a transition, identify open drug claims, pending authorizations, outstanding appeals, unposted remits, and unresolved charge batches. Ownership of those items must be explicit so current work does not disappear between teams.
01 · Establish the opening inventory
Separate existing A/R from new work, document payer deadlines, and confirm the records available for follow-up.
02 · Validate the first billing cycles
Reconcile treatment records to charges, claims to payer receipt, and remits to line-level balances before widening the operating scope.
03 · Keep policies and edits current
Review code effective dates, quarterly drug files, NCCI updates, payer bulletins, and access controls. Record the rule version behind consequential changes. Billing access should be governed by an applicable HIPAA business associate agreement, role-based permissions, and minimum necessary use of patient records.
CLIENT PERSPECTIVE
A Clearer View of the Work Behind Each Claim
For oncology leaders, useful billing support connects unresolved treatment claims to a responsible owner, a documented cause, and the next action.
BEFORE WE REVIEW YOUR PRACTICE
Questions Worth Asking First.
We begin by mapping the services, systems, professional and facility responsibilities, and payer requirements. Infusion drug reconciliation and radiation component billing need distinct review paths even when they belong to one organization.
No. Authorization is one condition in the claim workflow. Eligibility, coverage, documentation, code accuracy, benefit limits, and plan-specific claim requirements can still affect payment.
The assessment starts with your existing environment. We confirm access, treatment and charge records, exports or interfaces, and reconciliation needs before proposing the billing operating model.
Agree on a baseline and definitions for charge lag, first-pass acceptance, denial categories, drug payment variances, and aging movement. Segment results by payer, service, and location, with actions attached to material exceptions.
No. AI-assisted signals need review against the clinical record, code guidance, and applicable payer policy. Clinical decisions remain with the treating team; billing corrections need documented human accountability.
START WITH YOUR TREATMENT REVENUE
Which Part of Your Oncology Revenue Cycle Needs a Clearer Answer?
Bring the operational issue: drug payment variance, recurring infusion edits, authorization changes, radiation charges, or aging treatment claims. We will structure the conversation around the records, payer requirements, and handoffs behind it.
- Review the current billing model
- Identify the exception workflow
- Define practical next steps
Request an Oncology Billing Assessment
No obligation. No pressure. Just a practical conversation about your revenue cycle.